Akcie AbbVie (ABBV): FDA schválila novou kombinaci Venclexta-Calquence pro CLL — na co si dát v pondělí pozor
U.S. regulators approved a new first-line treatment for chronic lymphocytic leukemia combining AbbVie’s Venclexta and AstraZeneca’s Calquence, citing improved progression-free survival over standard therapy. AbbVie shares closed up 0.21% at $224.81 Friday. Barclays initiated coverage with an “overweight” rating and $275 target. Investors await further market reaction when trading resumes Monday.